Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Capital Expenditures (2020 - 2025)

Arcutis Biotherapeutics has reported Capital Expenditures over the past 6 years, most recently at $78000.0 for Q2 2025.

  • Quarterly results put Capital Expenditures at $78000.0 for Q2 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $686000.0 (up 379.72% YoY), and the annual figure for FY2025 was $686000.0, up 379.72%.
  • Capital Expenditures for Q2 2025 was $78000.0 at Arcutis Biotherapeutics, down from $608000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ARQT hit a ceiling of $608000.0 in Q1 2025 and a floor of $6000.0 in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $123000.0 (2022), compared with a mean of $172333.3.
  • Biggest five-year swings in Capital Expenditures: soared 1251.22% in 2021 and later plummeted 95.62% in 2022.
  • Arcutis Biotherapeutics' Capital Expenditures stood at $261000.0 in 2021, then tumbled by 52.87% to $123000.0 in 2022, then crashed by 95.12% to $6000.0 in 2023, then skyrocketed by 2283.33% to $143000.0 in 2024, then tumbled by 45.45% to $78000.0 in 2025.
  • The last three reported values for Capital Expenditures were $78000.0 (Q2 2025), $608000.0 (Q1 2025), and $143000.0 (Q3 2024) per Business Quant data.